ABSTRACT
A selective and sensitive high performance liquid chromatography-tandem mass spectrometric method was developed for the analysis of azelastine and its major metabolite, desmethylazelastine, in human plasma. Azelastine-(13)C, d(3) was used as internal standard. Azelastine, desmethylazelastine and the internal standard were extracted by a liquid-liquid extraction method and separation was performed under isocratic chromatographic condition. An abnormal signal loss issue for desmethylazelastine during method development was investigated and resolved. The developed method was precise and reproducible as shown by good intraday assay and interday assay precision (CV%≤ 12.8%). The calibration curve was linear over a range of 10.0/10.0-1000/200 pg/mL for azelastine/desmethylazelastine. The method was successfully applied to a pilot bioequivalence study subsequently.
Subject(s)
Chromatography, High Pressure Liquid/methods , Phthalazines/blood , Tandem Mass Spectrometry/methods , Drug Stability , Humans , Least-Squares Analysis , Liquid-Liquid Extraction , Phthalazines/chemistry , Phthalazines/pharmacokinetics , Reproducibility of Results , Sensitivity and SpecificityABSTRACT
A selective high performance liquid chromatography-tandem mass spectrometric (LC-MS/MS) method for the simultaneous determination of oxymorphone and its active metabolite 6-OH-oxymorphone in human plasma was developed and validated using oxymorphone-d(3) as the internal standard. Chromatographic conditions were optimized to separate oxymorphone from the other metabolite, oxymorphone-3-glucuronide, which may convert to oxymorphone in MS ion source, resulting in inaccurate quantitation of oxymorphone. Solid phase extraction (SPE) was used to extract oxymorphone and 6-OH-oxymorphone from plasma. SPE offered the advantage of being able to remove the unwanted metabolite, oxymorphone-3-glucuronide, through the wash step during the extraction. The developed method was precise and reproducible as shown by good linearity of calibration curves (correlation coefficients ≥0.9968 for oxymorphone and ≥0.9967 for 6-OH-oxymorphone) with high intraday assay and interday assay precision (CV% ≤11.0% for oxymorphone and ≤12.6% for 6-OH-oxymorphone) over a range of 35/25 - 5000/5000 pg/mL for oxymorphone/6-OH-oxymorphone. The method has been successfully applied to analyze oxymorphone and 6-OH-oxymorphone in plasma from 19 healthy volunteers in a bioequivalence study. A total of 1026 samples were analyzed. Good linearity (average correlation coefficient 0.9988 for oxymorphone and 0.9966 for 6-OH-oxymorphone) was achieved with calibration curves and high precision (CV% ≤5.9% for oxymorphone and ≤10.9% for 6-OH-oxymorphone) was obtained with QCs.
Subject(s)
Chromatography, High Pressure Liquid/methods , Oxymorphone/analogs & derivatives , Oxymorphone/blood , Tandem Mass Spectrometry/methods , Drug Stability , Humans , Least-Squares Analysis , Oxymorphone/chemistry , Oxymorphone/isolation & purification , Reproducibility of Results , Sensitivity and Specificity , Solid Phase ExtractionABSTRACT
A simple and reproducible high performance liquid chromatography-tandem mass spectrometric method was developed for methocarbamol analysis in human plasma. Methocarbamol and the internal standard (IS) were extracted by a protein precipitation method. Under isocratic separation condition the chromatographic run time was 3.0 min. The calibration curve was linear over a range of 150-12,000 ng/mL with good intraday assay and interday assay precision (CV%<10.9%). The method was proven to be sensitive and selective for the analysis of methocarbamol in human plasma for bioequivalence study.
